Abstract
In recent years, with the development of nuclear medicine imaging technology, radionuclide- labeled tumor imaging agents have shown unique advantages in the early diagnosis of tumors. Due to the relatively low cost of SPECT in the clinic with the convenient preparation and suitable properties of 99mTc, 99mTc-labeled tumor metabolic imaging agents prepared based on principles of tumor metabolism have gained considerable attention. This article briefly introduces the progress in the research of 99mTc-labeled glucose derivatives, amino acid derivatives, nucleotide derivatives, and other tumor metabolic imaging agents and proposes the prospects for the development of 99mTclabeled tumor metabolic imaging agents.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
